Chronic Obstructive Pulmonary Disease News and Research RSS Feed - Chronic Obstructive Pulmonary Disease News and Research

The World Health Organisation (WHO) has described Chronic Obstructive Pulmonary Disorder (COPD) as a global epidemic; an estimated 210 million people have COPD worldwide and more than 3 million people died of the condition in 2005, which is equal to 5% of all deaths globally that year. Total deaths from COPD are projected to increase by more than 30% in the next 10 years without interventions to cut risks, particularly exposure to tobacco smoke.
STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that STIOLTO RESPIMAT (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the United States. [More]
Long-term smokers and ex-smokers have respiratory-related impairments

Long-term smokers and ex-smokers have respiratory-related impairments

More than half of long-term smokers and ex-smokers who are considered disease-free because they passed lung-function tests have respiratory-related impairments when more closely evaluated with lung imaging, walking and quality-of-life tests. Many of those people likely have the earliest stages of chronic obstructive pulmonary disease, an incurable progressive disease (COPD) that is the third leading cause of death in the United States. [More]

Helmholtz Zentrum München scientists investigating molecular causes of COPD

At present, there is a lack of effective treatments that target the causes of chronic obstructive pulmonary disease (COPD). Scientists of the Comprehensive Pneumology Center at Helmholtz Zentrum München are therefore investigating the molecular causes of COPD in order to intervene specifically. [More]
Pulmatrix announces new inhaled anti-infective therapy to treat CF-associated fungal infections

Pulmatrix announces new inhaled anti-infective therapy to treat CF-associated fungal infections

Pulmatrix, Inc., a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced a new drug candidate, PUR1900, an inhaled anti-infective to treat fungal infections associated with cystic fibrosis (CF). [More]
Pulmatrix completes previously announced merger and closes $10 million in private placement

Pulmatrix completes previously announced merger and closes $10 million in private placement

Pulmatrix, Inc., previously known as Ruthigen, Inc., today announced the completion of its previously announced merger, effective June 15, 2015, and the closing of a private placement generating aggregate gross proceeds of $10.0 million. Participants in the private placement included pre-merger investors in Pulmatrix such as funds affiliated with 5AM Ventures, ARCH Venture Partners and Polaris Partners, as well as funds affiliated with Altitude Life Science Ventures. [More]
Pulmatrix signs ex-U.S. development agreement with Mylan for bronchodilator therapy

Pulmatrix signs ex-U.S. development agreement with Mylan for bronchodilator therapy

Pulmatrix, a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced that it has entered into an ex-U.S. development agreement with Mylan N.V., one of the world's leading global pharmaceutical companies. [More]
Lung cancer patients with comorbid conditions face higher risk of death

Lung cancer patients with comorbid conditions face higher risk of death

Lung cancer patients with comorbid conditions such as chronic obstructive pulmonary disease, diabetes, or congestive heart failure had a higher risk of death than lung cancer patients without comorbid conditions, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. [More]
Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Hospira, Inc., a global leader in biosimilars, today announced the results of an independent clinical study, showing patients with rheumatic diseases experienced comparable clinical effectiveness and safety after switching from Remicade™ to Inflectra. [More]
People across the world are living longer but spending more time in ill health

People across the world are living longer but spending more time in ill health

People across the world are living longer but spending more time in ill health as rates of nonfatal diseases and injuries - including diabetes and hearing loss - decline more slowly than death rates, according to a new analysis of 301 diseases and injuries in 188 countries. [More]
GBD analysis shows over 95% of global population has health problems

GBD analysis shows over 95% of global population has health problems

Just one in 20 people worldwide (4·3%) had no health problems in 2013, with a third of the world's population (2·3 billion individuals) experiencing more than five ailments, according to a major new analysis from the Global Burden of Disease Study (GBD) 2013, published in The Lancet. [More]
Transitional and progressive care can help patients achieve functional recovery faster in post-acute care

Transitional and progressive care can help patients achieve functional recovery faster in post-acute care

Transitional care has emerged as a way to reduce hospital readmissions, and progressive care nurses can play an integral role in efforts to help patients achieve functional recovery faster in post-acute care, according to an article in the June issue of Critical Care Nurse. [More]

Airway granulocytes potential CF biomarker for fungal lung disease

Researchers have found that accumulation in the airways of CXCR4+ granulocytes is associated with chronic colonisation by the fungus Aspergillus fumigatus. [More]
Pulmonary rehabilitation ‘should include sleep assessment’

Pulmonary rehabilitation ‘should include sleep assessment’

Researchers say that pulmonary rehabilitation programmes for patients with moderate to severe chronic obstructive pulmonary disease should include sleep assessment. [More]
Challenge remains for early COPD detection in primary care

Challenge remains for early COPD detection in primary care

Exhaled carbon monoxide testing in primary care has no effect on patient acceptance of screening for chronic obstructive pulmonary disease, research shows. [More]
Therapy for genetically-caused emphysema slows progression of lung disease

Therapy for genetically-caused emphysema slows progression of lung disease

A landmark clinical study in the Lancet provides convincing evidence that a frequently overlooked therapy for genetically-caused emphysema is effective and slows the progression of lung disease. [More]
Clementia Pharmaceuticals commences multi-center study of patients with fibrodysplasia ossificans progressiva

Clementia Pharmaceuticals commences multi-center study of patients with fibrodysplasia ossificans progressiva

Clementia Pharmaceuticals, Inc. today announced that it has commenced enrollment in the second part (Part B) of its natural history study in patients with fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling congenital myopathy characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) that result in the formation of new, abnormal (heterotopic) bone in muscles, tendons and ligaments. [More]
Airway and systemic inflammation predict COPD exacerbation

Airway and systemic inflammation predict COPD exacerbation

Researchers have found a link between increased airway and systemic inflammation and frequent exacerbations in patients with chronic obstructive pulmonary disease. [More]
FEV1/FVC lower limit of normal aids surgery risk stratification in COPD

FEV1/FVC lower limit of normal aids surgery risk stratification in COPD

Researchers say that using the lower limit of normal of the forced expiration volume in 1 second/forced vital capacity ratio improves risk stratification in patients with chronic obstructive pulmonary disease undergoing thoracic surgery. [More]
Mucus dehydration may contribute to chronic bronchitis

Mucus dehydration may contribute to chronic bronchitis

Mucus dehydration may lead to reduced mucociliary clearance and symptoms of chronic bronchitis, research suggests. [More]
Prediagnostic lung function impairment common in older asthma patients

Prediagnostic lung function impairment common in older asthma patients

Older adults with newly diagnosed asthma are not only more likely to have pre-existing lung function impairment than younger adults, but they also experience a more rapid decline of lung function, a Danish team reports in Respiratory Medicine. [More]
Advertisement